Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor

Vesci,Loredana; Milazzo,Ferdinando  Maria; Carollo,Valeria; Pace,Silvia; Giannini,Giuseppe

doi:10.3892/ijo.2014.2575

Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor

Authors:
- Loredana Vesci
- Ferdinando Maria Milazzo
- Valeria Carollo
- Silvia Pace
- Giuseppe Giannini
View Affiliations

Affiliations: Research & Development, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Pomezia, Italy
Published online on: August 1, 2014 https://doi.org/10.3892/ijo.2014.2575
Pages: 1421-1429
Copyright: © Vesci et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

4-Amino substituted resorcino-isoxazole (SST0116CL1) (property of Sigma-Tau Research Switzerland S.A.) is a potent, second generation, small-molecule heat shock protein 90 inhibitor (Hsp90i). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein degradation and tumor growth inhibition. The aim of the study was to assess SST0116CL1 in various solid and haematological tumors. The antitumor properties of SST0116CL1 were assessed using in vitro cell proliferation and client protein degradation assays and in vivo different tumor xenograft models. Pharmacokinetic (PK) data were also generated in tumor-bearing mice to gain an understanding of optimal dosing schedules and regimens. SST0116CL1 was shown to inhibit recombinant Hsp90α and to induce the destabilization of different client proteins, often overexpressed and constitutively activated in different types of hematological or solid human tumors. In preclinical in vivo studies, it was revealed to induce antitumor effects in murine models of leukemia and of gastric and ovarian carcinoma. A modulation of PD biomarkers in terms of downregulation of Hsp90 client proteins in tumor-bearing mice was found. SST0116CL1 is a new clinical candidate for cancer therapy. The antitumor property of SST0116CL1, likely due to direct inhibition of the Hsp90 enzymatic activity, may prove to be a critical attribute as the compound enters phase I clinical trials.

View Figures

View References

1	Li J and Buchner J: Structure, function, and regulation of the Hsp90 machinery. Biomed J. 36:106–117. 2013. View Article : Google Scholar
2	Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K, Motoki T, Tomono Y, Fukazawa T, Shirakawa Y, Yamatsuji T, Matsuoka J and Takaoka M: Hsp90 and its inhibitors. Oncol Rep. 23:1483–1492. 2010.PubMed/NCBI
3	Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005. View Article : Google Scholar : PubMed/NCBI
4	Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K and Gilles FJ: Targeting HSP90 for cancer therapy. Br J Cancer. 100:1523–1529. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S and Banerji U: First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 19:3671–3680. 2013. View Article : Google Scholar : PubMed/NCBI
7	Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T and Rosen LS: A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. Biomed Central Cancer. 13:152–161. 2013.
8	Soga S, Akinaga S and Shiotsu Y: Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 19:366–376. 2013. View Article : Google Scholar : PubMed/NCBI
9	Li J, Soroka J and Buchner J: The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperons. Biochim Biophys Acta. 1823.624–635. 2012.PubMed/NCBI
10	Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L and Workman P: NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
11	Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C and Chène P: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10:R332008. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Trepel JB, Neckers LM and Giaccone G: STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs. 11:1466–1476. 2010.PubMed/NCBI
13	Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S and Anderson KC: SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 113:846–855. 2009. View Article : Google Scholar
14	Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J and London C: The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol. 36:1266–1277. 2008. View Article : Google Scholar
15	Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF and Burrows FJ: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 8:921–929. 2009. View Article : Google Scholar : PubMed/NCBI
16	Picard D: Heat shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci. 59:1640–1648. 2002. View Article : Google Scholar : PubMed/NCBI
17	Baruchello R, Simoni D, Grisolia G, Barbato G, Marchetti P, Rondanin R, Mangiola S, Giannini G, Brunetti T, Alloatti D, Gallo G, Ciacci A, Vesci L, Castorina M, Milazzo FM, Cervoni ML, Guglielmi MB, Barbarino M, Foderà R, Pisano C and Cabri W: Novel 3.4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90. J Med Chem. 54:8592–8604. 2011. View Article : Google Scholar : PubMed/NCBI
18	Jhaveri K and Modi S: Hsp90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol. 65:471–517. 2012. View Article : Google Scholar : PubMed/NCBI
19	Patel HJ, Modi S, Chiosis G and Taldone T: Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov. 6:559–587. 2011. View Article : Google Scholar : PubMed/NCBI
20	Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic Hsp90 complex in cancer. Nat Rev Cancer. 10:537–549. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ramanathan RK and Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S and Egorin MJ: Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygenldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res. 13:1769–1774. 2007. View Article : Google Scholar : PubMed/NCBI
22	Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP and Belani CP: Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol. 28:1520–1526. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mimnaugh EG, Chavany C and Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 271:22796–22801. 1996. View Article : Google Scholar : PubMed/NCBI
24	Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM and Mendel DB: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63:7345–7355. 2003.PubMed/NCBI
25	Gilliland DG and Griffin JD: Role of FLT3 in leukemia. Curr Opin Hematol. 9:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
26	Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL and Heise C: CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft model of human acute myelogenous leukemia. Clin Cancer Res. 11:5281–5291. 2005.PubMed/NCBI
27	Fathi AT and Chabner BA: FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 16:1162–1174. 2011. View Article : Google Scholar : PubMed/NCBI
28	Gottesman MM, Bates SE and Fojo T: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
29	McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO and Erlichman C: P-glycoprotein mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 68:7419–7427. 2008. View Article : Google Scholar : PubMed/NCBI
30	Banerji U, O’Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P and Judson I: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
31	Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P: DT Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 91:1940–1949. 1999. View Article : Google Scholar : PubMed/NCBI
32	Hostein I, Robertson D, DiStefano F, Workman P and Clarke PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61:4003–4009. 2001.PubMed/NCBI
33	Ellis LM and Hicklin DJ: Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 15:7471–7478. 2009. View Article : Google Scholar : PubMed/NCBI